Company Description
Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis.
Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments.
This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing.
We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.
| Country | Switzerland |
| Founded | 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Luca Santarelli |
Contact Details
Address: Aeschenplatz 6 Basel, 4052 Switzerland | |
| Phone | +41 61 551 75 75 |
| Website | windwardbio.com |
Stock Details
| Ticker Symbol | WWB |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2145089 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Luca Santarelli | Chief Executive Officer and Chair of the Board of Directors |
| Claudia D’Augusta | Chief Financial Officer |
| Omar Khwaja | Chief Medical Officer |
| Kevin Harris | Chief Operating Officer |
| Scott Applebaum | Chief Legal and Corporate Development Officer |
| David P. Bonita | Director |
| Timothy Anderson | Director |
| Naveed I. Siddiqi | Director |
| Iqbal Mufti | Director |
| Otello Stampacchia | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Oct 23, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Oct 13, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 21, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 27, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 24, 2026 | DRS | [Cover] Draft Registration Statement |